The CGD Podcast – Episode Summary

Title: US-India Intellectual Property Rift - Arvind Subramanian and Kimberly Elliott
Host: Center for Global Development (Lawrence MacDonald)
Guests: Arvind Subramanian (Senior Fellow, CGD & Peterson Institute), Kimberly Elliott (Senior Fellow, CGD)
Date: April 14, 2014

Episode Overview

This episode dives into the escalating US-India trade tensions over intellectual property rights (IPR), particularly in the context of pharmaceuticals. The discussion explains the possible US Trade Representative (USTR) action to designate India as a "priority foreign country" for alleged IPR violations, the implications of such a move, and the broader issues of access to medicines, innovation incentives, and development. The conversation also explores how these disputes fit into global trade rules and the wider US-India relationship.

Key Discussion Points & Insights

1. Background: Declining US-India Economic Relations

• Recent context: Series of trade disputes, culminating in the USTR considering downgrading India for IPR violations.
• Potential timing issue: USTR announcement could coincide with or precede the inauguration of a new Indian government (late April to early May 2014).
  • "If India were to be downgraded, it would be clubbed with Ukraine and Paraguay as the most egregious countries in terms of respecting intellectual property rights." (Arvind, 01:00)

2. Significance of the "Priority Foreign Country" Designation

• Rarely used tool; carries major diplomatic and trade signal.
• Historically mainly used with Ukraine; the move against India would be nearly unprecedented.
• USTR has been politically careful with this designation, especially when targeting WTO members.
  • "The USTR is pretty careful. They are pretty politically attuned in using these tools." (Kim, 03:49)

3. Big Pharma’s Role and Symbolic Importance

• US pharmaceutical industry exerts strong domestic pressure to sanction India.
• Concern is not just India's practices, but that India could set a precedent for other developing countries.
  • "What India has been doing on intellectual property is potentially a model for other developing countries to emulate... the consequences for Big Pharma around the world go way beyond India." (Arvind, 04:37)
• The act of creating concern may itself be a lobbying success, even if severe action is not taken.

4. Roots of the Dispute: Generic Drugs, Compulsory Licensing, and TRIPS

• India's generic drug industry and compulsory licenses enable low-cost versions of patented drugs, often impacting drugs patented in the US.
• India points to consistency with WTO's TRIPS agreement, which allows flexibility for developing countries.
• Major cases: Indian Supreme Court upheld refusal to grant patents; compulsory licenses issued for certain cancer drugs.
  • "In both cases the Indians claim that they are... consistent with WTO rules." (Arvind, 09:43)
• US (and Big Pharma) claim rule violations but avoid WTO cases, fearing loss and weakened legitimacy.
  • "For some reason the US is not willing to do that, partly because it fears that it might lose that case and therefore its legitimacy will be undermined." (Arvind, 10:28)

5. Rule of Law and Perceived Hypocrisy

• Arvind notes the irony that India applies robust, transparent rule of law in IPR cases, sometimes more than in its domestic economic system.
• US doesn't acknowledge India's legal due process if outcomes go against American interests.
  • "If we had such rule of law in the rest of the Indian economic system, India's per capita GDP would be five times as big." (Arvind, 11:13)

6. Development Dimension: Balancing Innovation and Access

• Intellectual property is about balancing incentives for innovation with broad societal access to innovations.
• This balance should be different in developed vs. developing countries; for the latter, strict IPR can mean transferring rents to rich economies.
  • "Intellectual property is all about striking a balance. You want to incentivize innovation on the one hand, but then the societal benefits come from spreading those innovations as broadly as possible." (Kim, 14:30)
• In pharmaceuticals, market size matters: Larger emerging markets may now warrant higher IPR contributions than before.
  • "Even since the TRIPS negotiations... Brazil, India and China have become very big markets." (Arvind, 16:28)
• Differential (tiered) pricing is seen as a mechanism to balance incentives and access in big emerging markets.

7. WTO as Arbitration Mechanism (or Not)

• Both guests suggest that truly disputed aspects of Indian law should be tested at the WTO.
• US reluctance to bring cases underscores uncertainty about winning and the ambiguous nature of WTO rules on several IPR issues.
  • "...If there are areas where Indian law does seem to be in violation... rather than going this unilateral route, they should take those to the WTO and try and get those upheld." (Kim, 19:52)

8. Strategic & Economic Advice

• For the US:

  • Avoid escalating with a "priority foreign country" designation; let India’s new government settle in and repair wider trade ties.
  • Expand discussion beyond pharma/IPR to broader strategic and economic concerns.
    • "Don't even go towards, don't even get close to naming India as a priority foreign country. Let a new government come into power, start a new dialogue on... broader issues because those need to be restored and repaired." (Arvind, 21:34)

• For India:

  • Tackle other sources of foreign business uncertainty (e.g., erratic taxation).
  • Be open to negotiating specific IPR provisions, especially where current laws may be unnecessarily provocative without serving core national interests.
    • "India can very well meet its basic objectives... while respecting intellectual property. And it doesn't need to have these laws which are really red rags to a bull." (Arvind, 23:09)

Notable Quotes & Memorable Moments

• Arvind Subramanian:

  • "If we had such rule of law in the rest of the Indian economic system, India's per capita GDP would be five times as big." (11:13)
  • "Don't even go towards, don't even get close to naming India as a priority foreign country... Let a new government come into power, start a new dialogue on... broader trade issues and broader economic issues because those need to be restored and repaired." (21:34)

• Kimberly Elliott:

  • "The USTR is pretty careful. They are pretty politically attuned in using these tools." (03:49)
  • "Intellectual property is all about striking a balance. You want to incentivize innovation on the one hand, but then the societal benefits come from spreading those innovations as broadly as possible." (14:30)
  • "If USTR were to designate India as a priority foreign country, it would then trigger an investigation ... And if the US tried to take any action outside of WTO then ... India [should] take the US to the WTO for any unilateral action." (24:18)

Timestamps for Critical Segments

• US-India Trade Relations & USTR Action Explained: 01:33-03:28
• Big Pharma’s Influence and International Implications: 04:32-06:32
• Substance of the Dispute: India’s Generics, Compulsory Licenses: 07:26-10:24
• Rule of Law and US Attitudes: 10:24-12:29
• Development & Access to Medicines Framework: 14:30-17:16
• Differential Pricing and Big Emerging Markets: 17:16-19:45
• WTO as a Dispute Resolution Mechanism: 19:45-21:34
• Advice for US and India Trade Policy: 21:34-24:50

Summary Table: Principal Arguments and Policy Suggestions

| Stakeholder | Main Concerns | Suggested Course | |---------------------|-------------------------------------|-------------------------| | US Pharma/USTR | IPR enforcement, global precedent | Use WTO, avoid escalation| | Indian Govt | Affordable drug access, legal legitimacy | Open to negotiation (remove unnecessary legal irritants)| | Developing Countries | Access vs. incentive balance | Advocate flexibility; exploit TRIPS provisions| | Global Development Advocates | Ensure access to essential medicines | Push for differential pricing, balanced IPRs |

Final Takeaways

• The US-India IPR dispute is not simply about legal compliance, but global leadership, development, and access to medicines.
• Both sides should favor dialogue, WTO-driven dispute resolution, and balancing strategic interests over punitive or symbolic actions.
• The framework for IPR disputes in a changing global economy should reflect the new realities of emerging market sizes and capabilities.
  • "There is much more to the relationship than pharmaceuticals." (Arvind, 22:31)

Listeners interested in global trade, intellectual property, and development will gain nuanced perspectives and policy insights from this episode. The discussion skillfully balances legal, economic, and humanitarian dimensions, making a complex topic accessible and actionable.